On the stock market since 2016, it operates in the world of health and science. It has 365 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
An average decline of 7% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $67.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 19 buys and 12 sells. Management buying with its own money is usually read as a good sign.
A loss of $67.8M against $67.0M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, NH sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NH is a high-risk stock — not yet profitable, and its future rides on its product catching on.